Gynecological Devices Market

December 24, 2020

To Prosper on Back of Rising Global Burden of Gynecological Disorders, Valuation to Touch US$ 25,267.43 Mn by 2027: TMR

Gynecological diseases are the primarily the diseases that involve women’s reproductive system. Globally, these have a high burden and also mortality, such as the prevalence of endometrium cancer and cervical cancer.

Sexually transmitted disease (STD) have been particularly prevalent in the patient population. All these trends shape the prospects of the gynecological devices market.

Rapid advances have been made in both the clinical expertise of surgeons and the devices that are used for minimally invasive surgeries. A case in point is the growing demand for new technologies in devices used in minimally invasive hysterectomies.

Growing demand for gynecological devices in laparoscopy and endoscopy has helped propelled revenue expansion in the market. Globally, the gynecological devices market is expected to reach worth of US$ 25,267.43 Mn, clocking CAGR of 3.8 % from 2019 to 2027.

Request for Analysis of COVID-19 Impact on Gynecological Devices Market – https://www.transparencymarketresearch.com/covid19.php

Key Findings of Gynecological Devices Market

  • In 2018, the global valuation of the market was pegged at US$ 17,449.09 Mn
  • The market is garnering new opportunity from continuing shift to minimally invasive surgeries
  • In the above regard, da Vinci robotic platform and single port laparoscopic surgery (SPLS) are popular approaches
  • Of the various products, surgical device segment held the major share in 2018
  • Regionally, North America held the major share in 2018
  • The North America gynecological devices market is trailed by Europe
  • Opportunities in Asia Pacific expected to make rapid expansion during the forecast period
  • China a potentially lucrative country market in Asia Pacific

Request Brochure of Gynecological Devices Market Report – https://www.transparencymarketresearch.com/brochure.php

Gynecological Devices Market: Key Driving Factors and Promising Avenues

  • Growing severity of gynecological disease is a key trend bolstering the demand in the gynecological devices market
  • Some of the common gynecological conditions are uterine fibroids, ovarian cysts, abnormal vaginal bleeding, genital tract infections, and vagina skin disorders. Over the years, women have growing increasingly aware of the burden of these, and are making clinic visits to address their concerns. This is a key factor underpinning the sales in the gynecological devices market.
  • In developing regions, the burden of HIV and sexually transmitted diseases is high, both due to living working conditions and improving healthcare infrastructure in these parts of the world.
  • The growing incidence of endometrium cancer and its substantial mortality are key factors boosting the demand for minimally invasive surgical procedures in the patient population. Rapid advancements have been brought by medical device makers to make the surgeries minimally invasive.
  • Ovarian cancer, one of the most common cancer in women in the world, has nudged women to give importance to clinical conditions of the related gynecologic diseases.
  • Rapidly increasing traction of robotics and other automation technologies in gynecological disorders has been expanding the avenue in the gynecological devices market.

Purchase the Gynecological Devices Market Report – https://www.transparencymarketresearch.com/checkout.php

Gynecological Devices Market: Competitive Dynamics and Key Impediments for Stakeholders

The regulatory outlook does not seem very favorable to gynecological devices market players in key regions. For instance, the approval policies of the U.S Food and Drug Administration (FDA), such as 510(k) and premarket approval (PMA) norms, need to be more conducive to the marketing of pioneer products. On the other hand, there have been significant number of product recalls vis the PMA processes in the U.S. in the last few years. Moreover, even large medical device manufacturers may be reluctant to bear the cost of stringent documentation.

Nevertheless, medical device makers are leaning on leveraging the strength of robotics surgeries to expand their revenue-earning potential. A large number of players make the landscape increasingly fragmented. Some of the well-entrenched players are Karl Storz Gmbh & Co., Hologic, Inc., Olympus Corporation, Stryker Corporation, and Johnson & Johnson Services.

Explore Transparency Market Research’s award-winning coverage of the global Healthcare Industry:

Contraceptives Market: https://www.transparencymarketresearch.com/contraceptives-market.html

Endoscopy Ultrasound Market: https://www.transparencymarketresearch.com/endoscopy-ultrasound-market.html

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version